Medical Search Australia Trusted by 250,000+ buyers

ASMI welcomes announcement for deferral of codeine decision

24 November, 2015

The Australian Self Medication Industry (ASMI) welcomed the Therapeutic Goods Administration's (TGA) announcement that a final decision on the scheduling of over-the-counter codeine medicines will be deferred.

ASMI Chief Executive Officer, Deon Schoombie, said: "This is a positive outcome. It reflects the views of the great majority of stakeholders and will allow consumers to continue to have appropriate pharmacy access to codeine-containing medicines.

"There is no evidence that cold/flu medicines are being misused therefore current scheduling remains appropriate for them.

"ASMI maintains a real time monitoring system is the most appropriate way to reduce potential misuse of codeine-containing analgesics.

"The industry, pharmacy and consumer groups have jointly developed a real time monitoring prototype, which will help pharmacists to determine if a codeine-containing analgesic is appropriate for a particular condition or consumer. We will continue to work with these groups to ensure the timely implementation of the system.

"Real time monitoring will assist pharmacists to identify at-risk consumers, facilitate access to education materials and support referral to a pain specialist when necessary. It will also ensure the majority of consumers who use codeine-containing analgesics responsibly still have pharmacy access to them.

"ASMI believes the real-time monitoring system should be part of a package of measures to address potential misuse of codeine-containing analgesics, including front-of-pack warnings about the risk of codeine addiction and information/training resources for pharmacists and consumers," he added.

Have your say...

We welcome thoughtful comments from readers
Reload characters
Type the characters you see in this box. This helps us prevent automated programs from sending spam.